Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat Trial
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase II trial tests the effect of the botensilimab in combination with balstilimab in treating patients with stage II/III colorectal adenocarcinoma with detectable circulating tumor (ct) deoxyribonucleic acid (DNA) in the blood. Immunotherapy with monoclonal antibodies, such as botensilimab and balstilimab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Giving botensilimab and balstilimab may be an effective combination to remove any remaining microscopic cancer cells in the bloodstream in patients with stage II/III colorectal adenocarcinoma. In addition, clearing the ctDNA from the blood may serve as an early indicator of treatment response.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Dobry ogólny stan zdrowia (wydolność fizyczna stopnia 0-2)
- •Wystarczająca liczba krwinek białych (neutrofili co najmniej 1000/mcL)
- •Wystarczająca liczba płytek krwi (co najmniej 100 000/mcL)
- •Prawidłowe funkcje wątroby (bilirubina do 1,5x normy)
- •Prawidłowe funkcje nerek (oczyszczanie kreatyniny co najmniej 40 mL/min)
- •Potwierdzony histologicznie rak jelita grubego (adenokarcynoma) II lub III stopnia
- •Ukończone chirurgiczne usunięcie guza i zaplanowane chemioterapie, ze śladami nowotworu w krwi (ctDNA)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 29, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (2)
Ochsner Medical Center Jefferson
New Orleans, United States
UT MD Anderson Cancer Center
Houston, United States
Trial contact
Site Public Contact
Lingling Du
PRINCIPAL_INVESTIGATOR
Site Public Contact
Kanwal P. Raghav
PRINCIPAL_INVESTIGATOR
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/16/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.